معرفی
Professor Phillip Robinson is a renowned academic in Medicine at the University of Sydney and University of Newcastle, leading the Cell Signalling Unit at the Children’s Medical Research Institute (CMRI) in Sydney. He holds a prestigious Senior Principal Research Fellowship from the NHMRC. His research focuses on understanding synaptic transmission mechanisms and developing drugs targeting dynamin proteins to treat epilepsy, cancer, and neurodegenerative diseases. Key contributions include discoveries in endocytosis regulation, phosphoproteomics, and dynamin inhibitor drug development.
Robinson earned a B.Sci. (Hons) in Biochemistry from the University of Sydney and a PhD in Medical Biochemistry from the University of Newcastle. His postdoctoral work spanned institutions in the USA, Australia, and the UK. He currently leads a team of 23 researchers, integrating biochemistry, cell biology, and medicinal chemistry to bridge basic science with clinical applications.
Research interests center on dynamin’s role in synaptic vesicle recycling and disease. His lab’s work has identified phosphoproteomic markers in endocytic proteins and developed dynamin inhibitors like the dynoles and pitstops. These compounds are being tested as potential therapies for epilepsy, cancer, and chronic kidney disease.
Publications span proteomics, drug discovery, and molecular biology, with recent focuses on cancer biomarkers, CAR-T cell therapy, and endocytosis pathways in neuroblastoma. Awards include NHMRC Senior Principal Research Fellowships.
He advises on proteomic technologies and collaborates with medicinal chemists to advance therapeutic pipelines. His team’s work on dynamin’s role in leukemia stem cells and cytokinesis failure further highlights translational research impacts.
